Last updated: 2026-09-16 09:45:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
ImageneBio, Inc. (IMA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $5,03, with a market capitalisation of $56,76M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,94 to $9,10. This page covers its latest market performance, valuation, price trends and company information.
$56,76M | |
$4,99 | |
$65,00 | |
$3,94 | |
$5,00 | |
13,93K | |
11,78K | |
-- | |
$9,10 | |
$3,94 | |
-- | |
-- |
ImageneBio, Inc. (IMA) is trading at $4,89 in pre-market trading as of 2026-09-15 20:11:00, down 2,30% ($0,12) from the previous close of $5,00
Pre-market trading shows how investors are pricing IMA before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, ImageneBio, Inc. (IMA) moved from $4,85 to $5,03, representing a gain of 3,79% ($0,18).
The stock traded between $4,73 and $5,39 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 17,66 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 21,2%
IMA is currently trading at $5,03, placing it 21,2% of the way from its 52-week low of $3,94 to its 52-week high of $9,10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 18 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of ImageneBio, Inc. (IMA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.